Stevanato Group S.p.A. (FRA:87N)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.41B -25.1% |
| Revenue (ttm) | 1.20B +7.0% |
| Net Income | 141.35M +12.6% |
| EPS | 0.51 +11.1% |
| Shares Out | n/a |
| PE Ratio | 31.17 |
| Forward PE | 25.87 |
| Dividend | 0.05 (0.34%) |
| Ex-Dividend Date | Jun 11, 2026 |
| Volume | n/a |
| Open | 16.30 |
| Previous Close | 16.00 |
| Day's Range | 16.00 - 16.30 |
| 52-Week Range | 11.30 - 23.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector... [Read more]
Financial Performance
In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.
Financial StatementsNews
Stevanato Group Transcript: 46th Annual William Blair Growth Stock Conference
With a 75-year legacy, the company has achieved double-digit growth by focusing on high-value pharmaceutical packaging and drug delivery systems. Major investments in global capacity and R&D support leadership in biologics and GLP-1, with high-value products now nearly half of revenue.
Stevanato Group assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Stevanato Group (STVN) with an Outperform rating and $21 price target The firm stated in a research note on Life Science Tools & Diagnostics that…
Stevanato Group Transcript: Bank of America Global Healthcare Conference 2026
Strong growth in high-value solutions, especially for biologics and GLP-1s, is driving revenue and margin expansion. Major capacity investments in the U.S. and Italy are nearly complete, supporting future growth and improved cash flow. Adjusted EBITDA margin is on track to reach 30% by 2027.
Stevanato Group Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% revenue growth at constant currency, led by strong BDS segment performance and high-value solutions, especially GLP-1s. Engineering margins improved despite lower revenue. Guidance for 2026 is maintained, with robust demand for syringes and cartridges and ongoing capacity expansions.
Stevanato Group Earnings release: Q1 2026
Stevanato Group released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Stevanato Group Slides: Q1 2026
Stevanato Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Participate in Three Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group management to meet with KeyBanc
Meeting to be held in New York on March 26 hosted by KeyBanc.
Stevanato Group Slides: Investor presentation
Stevanato Group has posted slides in relation to its latest quarterly earnings report, which was published on March 21, 2026.
Stevanato Group Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong growth in high-value solutions and biologics drove margin expansion and record revenues in 2025, with further gains expected in 2026. Major capacity investments in sterile cartridges and drug delivery systems support long-term growth, while new plants are set to deliver high profitability.
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group price target lowered to $19 from $24 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Stevanato Group (STVN) to $19 from $24 and keeps an Equal Weight rating on the shares. The firm updated its model following…
Stevanato Group price target lowered to $32 from $37 at KeyBanc
KeyBanc lowered the firm’s price target on Stevanato Group (STVN) to $32 from $37 and keeps an Overweight rating on the shares. The firm notes the company’s Q4 print was…
Stevanato Group price target lowered to $26 from $32 at Citi
Citi lowered the firm’s price target on Stevanato Group (STVN) to $26 from $32 and keeps a Buy rating on the shares.
Stevanato Group price target lowered to $28 from $30 at BofA
BofA lowered the firm’s price target on Stevanato Group (STVN) to $28 from $30 and keeps a Buy rating on the shares. The firm notes Q4 results were ahead of…
Stevanato Group Earnings Call Transcript: Q4 2025
Fiscal 2025 saw strong revenue and margin growth, led by high-value solutions and robust GLP-1 demand. 2026 guidance anticipates continued BDS growth, margin expansion, and high-value solutions reaching up to 48% of revenue, despite currency and engineering headwinds.
Stevanato Group Annual report: Q4 2025
Stevanato Group has published its Q4 2025 annual report on March 4, 2026.
Stevanato Group Earnings release: Q4 2025
Stevanato Group released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Stevanato Group Slides: Q4 2025
Stevanato Group has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato Group price target lowered to $17.50 from $23 at Jefferies
Jefferies lowered the firm’s price target on Stevanato Group (STVN) to $17.50 from $23 and keeps a Hold rating on the shares. Injectable packaging Contract Manufacturing Organizations face headwinds f...
Stevanato Group assumed with an Equal Weight at Morgan Stanley
Morgan Stanley assumed coverage of Stevanato Group (STVN) with an Equal Weight rating and a price target of $24, down from $26. Life Science Tools and Diagnostics end market bright…